IARC – International Agency for Research on Cancer/World Health Organization shared on LinkedIn:
“IARC and partners compared a PCR test to immunohistochemistry, which is often unavailable in LMICs, to distinguish different molecular subtypes of breast cancer.
Knowing the subtype is essential to guiding therapy.
Findings are published in a new study in the journal Cancer Medicine.”
You can also read: monarchE: Abemaciclib Benefit Persists Across Nodal Subgroups in High-Risk HR+/HER2− Early Breast Cancer
